Product Details
| Product Name:
Gefarnate |
CAS No.:
51-77-4 |
| Purity:
98.36% |
Supply Ability:
10g |
| Release date:
2026/04/22 |
Product Introduction
Bioactivity
| Name | Gefarnate |
| Description | Gefarnate is a synthetic compound used for the treatment of gastric ulcers,and also used in the treatment of dry eye syndrome. |
| Animal Research | Conjunctival tissue isolated from rabbits was treated with gefarnate. Mucin-like glycoprotein was detected in the culture supernatant by an enzyme-linked lectin assay. Gefarnate ointment was topically applied to eyes once daily for 7 days in the rabbit dry-eye model, in which the lacrimal glands, Harderian gland, and nictitating membrane were removed, or for 4 weeks in the cat dry-eye model, in which the lacrimal gland and nictitating membrane were removed. Corneal epithelial damage was evaluated by measurement of corneal permeability by rose bengal in the rabbit model or by fluorescein staining in the cat model[1]. |
| In vivo | Gefarnate stimulated mucin-like glycoprotein secretion in conjunctival tissue in a dose-dependent manner. In the rabbit dry-eye model, application of gefarnate ointment to the eyes resulted in a dose-dependent decrease in rose bengal permeability in the cornea, with the effect being significant at concentrations of ≥0.3%. In the cat dry-eye model, application of gefarnate ointment resulted in a significant decrease in the corneal fluorescein staining score[1]. |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (9.98 mM), Sonication is recommended.
DMSO : 100 mg/mL (249.6 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | Gefarnate |
| Inhibitors Related | Clivatuzumab | TAB-004 | Ubletamig | Sontuzumab | Minretumomab | Anti-MUC17 Antibody | Oregovomab | Fudosteine | Clivatuzumab MMAE | Gatipotuzumab | Guaifenesin | Sofituzumab |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Approved Drug Library | ReFRAME Related Library | Drug Repurposing Compound Library | NO PAINS Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Bioactive Lipid Compound Library | Human Metabolite Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$15.00
|
|
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-02 |
|
|
$7.00
|
VIP8Y
|
Career Henan Chemical Co
|
2019-07-06 |
|
|
$10.00
|
|
Hubei XinRunde Chemical Co., Ltd.
|
2019-01-15 |
United States